Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04801420 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
A Phase 2 study of Lyme Borreliosis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 625
- Enrollment target
- 20
- Study locations
NCT04801420 is a Phase 2 study of Lyme Borreliosis that has completed, run by Pfizer. The registered enrollment target is 625 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT04801420, a Phase 2 study of Lyme Borreliosis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 625 participants
- Enrollment target
- 20
- Study locations
Study Summary
VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 50 months per subject.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLA15
Study Locations (20)
New York
- Meridian Clinical Research LLC - Binghamton
- Pfizer Vaccine Research and Development - Pearl River
- Rochester Clinical Research, Inc. - Rochester
- Richmond Behavioral Associates - Staten Island
- Advantage Clinical Trials - The Bronx
Connecticut
- New England Research Associates - Bridgeport
- Stamford Therapeutics Consortium - Stamford
- Chase Medical Research, LLC - Waterbury
- Pediatric Associates of Conn. PC - Waterbury
Pennsylvania
- Allegheny Health and Wellness Pavilion - Erie
- Liberty Family Practice - Erie
- Lockman & Lubell Pediatric Associates - Fort Washington
Rhode Island
- Hasbro Children's Hospital - Providence
- Rhode Island Hospital - Providence
- The Miriam Hospital - Providence
New Jersey
- Foundation Pediatrics - East Orange
- Med Clinical Research Partners, LLC - Irvington
Massachusetts
- Quest Diagnostics - Marlborough
Minnesota
- Clinical Research Institute, Inc. - Minneapolis
Ohio
- Velocity Clinical Research, Inc. - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 625 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2025-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04801420
The ClinicalTrials.gov registry entry for NCT04801420 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 625 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lyme Borreliosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04801420 reports 20 study locations spanning 8 distinct geographic areas - top geographies include New York, Connecticut, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04801420 about?
NCT04801420 is a clinical study titled "Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population". VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the stu...
What is the current status of trial NCT04801420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 625 participants. The study started on 2021-03-08. Estimated completion is 2025-07-02.
What conditions does trial NCT04801420 study?
This clinical trial studies the following conditions: Lyme Borreliosis.
What interventions are being tested in trial NCT04801420?
The interventions under investigation include: Placebo (BIOLOGICAL), VLA15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04801420?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04801420 being conducted?
This trial has 20 study locations across Connecticut, Massachusetts, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lyme Borreliosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.